Risks and benefits of biologic therapy for inflammatory bowel diseases

被引：88

作者：

D'Haens, Geert ^{[1
]}

机构：

[1] Imelda GI Clin Res Ctr, B-2820 Bonheiden, Belgium

来源：

GUT | 2007年 / 56卷 / 05期

关键词：

D O I：

10.1136/gut.2006.103564

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：725 / 732

页数：8

相关论文

共 49 条

[1]

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[2]

Complications of biological therapy for inflammatory bowel diseases [J].

Blonski, W ;

Lichtenstein, GR .

CURRENT OPINION IN GASTROENTEROLOGY, 2006, 22 (01) :30-43

[3]

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[4]

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].

Chung, ES ;

Packer, M ;

Lo, KH ;

Fasanmade, AA ;

Willerson, JT .

CIRCULATION, 2003, 107 (25) :3133-3140

[5]

The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].

Colombel, JF ;

Loftus, EV ;

Tremaine, WJ ;

Egan, LJ ;

Harmsen, WS ;

Schleck, CD ;

Zinsmeister, AR ;

Sandborn, WJ .

GASTROENTEROLOGY, 2004, 126 (01) :19-31

[6]

Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy [J].

Devos, SA ;

Van Den Bossche, N ;

De Vos, M ;

Naeyaert, JM .

DERMATOLOGY, 2003, 206 (04) :388-390

[7]

Utility of the antigen-specific interferon-γ assay for the management of tuberculosis [J].

Dheda, K ;

Udwadia, ZF ;

Huggett, JF ;

Johnson, MA ;

Rook, GAW .

CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (03) :195-202

[8]

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis [J].

Esteve, M ;

Saro, C ;

González-Huix, F ;

Suarez, F ;

Forné, M ;

Viver, JM .

GUT, 2004, 53 (09) :1363-1365

[9]

Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin [J].

Feagan, BG ;

Greenberg, GR ;

Wild, G ;

Fedorak, RN ;

Paré, P ;

McDonald, JWD ;

Dubé, R ;

Cohen, A ;

Steinhart, AH ;

Landau, S ;

Aguzzi, RA ;

Fox, IH ;

Vandervoort, MK .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2499-2507

[10]

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial [J].

Hanauer, SB ;

Sandborn, WJ ;

Rutgeerts, P ;

Fedorak, RN ;

Lukas, M ;

Macintosh, D ;

Panaccione, R ;

Wolf, D ;

Pollack, P .

GASTROENTEROLOGY, 2006, 130 (02) :323-332

← 1 2 3 4 5 →